RU2006110036A - Лечение глазных расстройств анти-cd20 - Google Patents
Лечение глазных расстройств анти-cd20 Download PDFInfo
- Publication number
- RU2006110036A RU2006110036A RU2006110036/13A RU2006110036A RU2006110036A RU 2006110036 A RU2006110036 A RU 2006110036A RU 2006110036/13 A RU2006110036/13 A RU 2006110036/13A RU 2006110036 A RU2006110036 A RU 2006110036A RU 2006110036 A RU2006110036 A RU 2006110036A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- eye
- mammal
- fragment
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (17)
1. Способ лечения глазного расстройства у млекопитающего, предусматривающий введение антагониста CD20 млекопитающему в количестве, эффективном для лечения глазного расстройства.
2. Способ по п.1, где антагонист состоит из антитела.
3. Способ по п.1, где млекопитающее является человеком.
4. Способ по п.2, где антитело не конъюгировано с цитотоксическим средством.
5. Способ по п.2, где антитело состоит из ритуксимаба.
6. Способ по п.2, где антитело состоит из гуманизированного 2H7.
7. Способ по п.2, где антитело конъюгировано с цитотоксическим средством.
8. Способ по п.1, который, по существу, состоит из введения антагониста млекопитающему.
9. Способ по п.1, где млекопитающее производит аутоантитела, которые связываются с более чем одним глазным антигеном, или имеет иммунные комплексы в глазу.
10. Способ по п.1, где глазное расстройство выбрано из группы, состоящей из увеита, ирита, тиреоидной болезни глаз или офтальмологии Грейвса, поражения глаз при болезни Бехчета, myasthenia gravis глаз, пемфигоида глаз, аутоиммунной ретинопатии, онхоцеркоза, эписклерита, склерита, рецидивирующего неврита зрительного нерва, зависимого от стероидов, поражения глаз при гранулематозе Вегенера, глазного осложнения Шегрена, ретинопатии, вызванной меланомой, и ретинопатии, вызванной раком.
11. Способ по п.1, где антитело является интактным антителом.
12. Способ по п.1, где антитело является фрагментом антитела, который содержит антигенсвязывающую область, которая связывает CD20.
13. Способ по п.12, где фрагмент антитела выбран из группы, состоящей из Fab, Fab', F(ab')2, Fv, одноцепочечного Fv-фрагмента (scFv) и диатела.
14. Способ по п.1, где антитело вводится внутривенно.
15. Способ по п.1, где антитело вводится посредством внутриглазничной, внутрикамерной, окологлазничной инъекции или инъекции в стекловидное тело.
16. Способ по п.15, где антитело является фрагментом антитела, который содержит антигенсвязывающую область, которая связывает CD20.
17. Способ по п.1, где антитело вводится в глаз местно.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49879103P | 2003-08-29 | 2003-08-29 | |
US60/498,791 | 2003-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2006110036A true RU2006110036A (ru) | 2006-08-10 |
Family
ID=34272728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006110036/13A RU2006110036A (ru) | 2003-08-29 | 2004-08-20 | Лечение глазных расстройств анти-cd20 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20050053602A1 (ru) |
EP (1) | EP1660129A2 (ru) |
JP (1) | JP2007504138A (ru) |
KR (1) | KR20060132554A (ru) |
CN (1) | CN1845755A (ru) |
AU (1) | AU2004270165A1 (ru) |
BR (1) | BRPI0412629A (ru) |
CA (1) | CA2535895A1 (ru) |
IL (1) | IL173351A0 (ru) |
MX (1) | MXPA06002134A (ru) |
NO (1) | NO20061412L (ru) |
RU (1) | RU2006110036A (ru) |
WO (1) | WO2005023302A2 (ru) |
ZA (1) | ZA200601218B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020027311A (ko) | 1999-05-07 | 2002-04-13 | 제넨테크, 인크. | B 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료 |
CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
JP5416338B2 (ja) * | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Cd20特異的抗体およびその使用方法 |
BR122020013239B1 (pt) * | 2003-11-05 | 2022-05-10 | Roche Glycart Ag | Anticorpo anti-cd20 humano tipo ii humanizado, seus usos, bem como composição farmacêutica |
US20060051345A1 (en) | 2004-06-04 | 2006-03-09 | Genentech, Inc. | Method for treating multiple sclerosis |
SV2006002131A (es) * | 2004-06-04 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento de lupus |
EP1781378A2 (en) * | 2004-07-22 | 2007-05-09 | Genentech, Inc. | Method of treating sjögren's syndrome |
CN101087807A (zh) * | 2004-10-05 | 2007-12-12 | 健泰科生物技术公司 | 治疗血管炎的方法 |
AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
ES2341484T3 (es) * | 2005-05-20 | 2010-06-21 | Genentech, Inc. | Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune. |
AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
WO2016081490A1 (en) | 2014-11-17 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
US11590223B2 (en) | 2018-08-31 | 2023-02-28 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
US4861579A (en) * | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
ATE196606T1 (de) * | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU8296098A (en) * | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
PL195870B1 (pl) * | 1998-08-11 | 2007-11-30 | Biogen Idec Inc | Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny |
US6224866B1 (en) * | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
EP1035172A3 (en) * | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
DK1194167T3 (da) * | 1999-06-09 | 2009-11-16 | Immunomedics Inc | Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
NZ516491A (en) * | 1999-07-12 | 2004-11-26 | Idec Pharmaceuticals Inc | Blocking immune response to a foreign antigen using an antagonist which binds to CD20 |
US20020006404A1 (en) * | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
JP2004500412A (ja) * | 2000-03-31 | 2004-01-08 | アイデック ファーマスーティカルズ コーポレイション | B細胞リンパ腫の治療のための抗サイトカイン抗体またはアンタゴニストおよび抗cd20の併用 |
NZ521540A (en) * | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU2001259142C1 (en) * | 2000-04-25 | 2006-11-23 | Biogen Idec Inc. | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
DK1296714T3 (da) * | 2000-06-22 | 2009-12-07 | Coley Pharm Gmbh | Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft |
CA2422076A1 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
US20030103971A1 (en) * | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
AU2002250352C1 (en) * | 2001-04-02 | 2009-04-30 | Genentech, Inc. | Combination therapy |
IL158316A0 (en) * | 2001-04-10 | 2004-05-12 | Univ Leland Stanford Junior | Therapeutic and diagnostic uses of antibody specificity profiles |
AU2002327037A1 (en) * | 2001-09-20 | 2003-04-01 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
US20030157108A1 (en) * | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
US20030147865A1 (en) * | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
KR20090088973A (ko) * | 2002-10-17 | 2009-08-20 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
KR20110044809A (ko) * | 2003-04-09 | 2011-04-29 | 제넨테크, 인크. | Tnf-알파 저해제에 대해 부적절한 반응을 하는 환자에서의 자가면역 질환의 치료법 |
-
2004
- 2004-08-20 RU RU2006110036/13A patent/RU2006110036A/ru not_active Application Discontinuation
- 2004-08-20 JP JP2006524757A patent/JP2007504138A/ja not_active Withdrawn
- 2004-08-20 WO PCT/US2004/027164 patent/WO2005023302A2/en active Application Filing
- 2004-08-20 CN CNA2004800249822A patent/CN1845755A/zh active Pending
- 2004-08-20 US US10/922,651 patent/US20050053602A1/en not_active Abandoned
- 2004-08-20 AU AU2004270165A patent/AU2004270165A1/en not_active Abandoned
- 2004-08-20 CA CA002535895A patent/CA2535895A1/en not_active Abandoned
- 2004-08-20 MX MXPA06002134A patent/MXPA06002134A/es not_active Application Discontinuation
- 2004-08-20 ZA ZA200601218A patent/ZA200601218B/en unknown
- 2004-08-20 EP EP04781779A patent/EP1660129A2/en not_active Withdrawn
- 2004-08-20 BR BRPI0412629-7A patent/BRPI0412629A/pt not_active IP Right Cessation
- 2004-08-20 KR KR1020067003992A patent/KR20060132554A/ko not_active Application Discontinuation
-
2006
- 2006-01-25 IL IL173351A patent/IL173351A0/en unknown
- 2006-03-28 NO NO20061412A patent/NO20061412L/no not_active Application Discontinuation
-
2007
- 2007-10-26 US US11/925,260 patent/US20090136492A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005023302A3 (en) | 2005-04-28 |
ZA200601218B (en) | 2007-05-30 |
BRPI0412629A (pt) | 2006-09-26 |
EP1660129A2 (en) | 2006-05-31 |
AU2004270165A1 (en) | 2005-03-17 |
NO20061412L (no) | 2006-03-28 |
US20050053602A1 (en) | 2005-03-10 |
IL173351A0 (en) | 2006-06-11 |
CA2535895A1 (en) | 2005-03-17 |
US20090136492A1 (en) | 2009-05-28 |
WO2005023302A2 (en) | 2005-03-17 |
MXPA06002134A (es) | 2006-05-31 |
JP2007504138A (ja) | 2007-03-01 |
KR20060132554A (ko) | 2006-12-21 |
CN1845755A (zh) | 2006-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006110036A (ru) | Лечение глазных расстройств анти-cd20 | |
US8633301B2 (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
CN106334187B (zh) | 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合 | |
AU2009321252B2 (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cylophosphamide | |
US9259406B2 (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
KR20220025946A (ko) | 항-egfr 항체 및 항체 약물 접합체 | |
JP2010528047A5 (ru) | ||
JP2010520290A5 (ru) | ||
CN110799535A (zh) | 抗folr1免疫缀合物与抗pd-1抗体的组合 | |
CA3225908A1 (en) | Treatment of anti-pla2r autoantibody-mediated membranous nephropathy | |
AU2007299582B2 (en) | Anti-cancer antibodies against Lewisy and Lewisb antigens | |
KR20190110063A (ko) | 항-vegfr-2 항체 | |
IL314344A (en) | Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma | |
WO2024112561A1 (en) | Methods for the treatment of myasthenia gravis | |
AU2005211669C1 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
RU2004137274A (ru) | Антитела против миелин-ассоциированного гликопротеина (mag) | |
IL311796A (en) | Anti-galectin-9 antibodies and their therapeutic uses | |
RU2021133162A (ru) | Способы лечения рака предстательной железы с помощью антитела к psma/cd3 | |
JPWO2021092380A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100112 |